Download Citation
Article Source:
A phase II open label clinical study of the safety, tolerability and efficacy of ILB® for Amyotrophic Lateral Sclerosis
Logan A,
Nagy Z,
Barnes NM,
Belli A,
Di Pietro V,
et al.
(2022)
A phase II open label clinical study of the safety, tolerability and efficacy of ILB® for Amyotrophic Lateral Sclerosis.
PLOS ONE 17(5): e0267183.
https://doi.org/10.1371/journal.pone.0267183